NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States

By Jorge Marrero, R. Fontana, G. Su, H. Conjeevaram, Dawn M. Emick, Anna S.F. Lok. Hepatology, 2002

665 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/81fd28a239b32c7272b0be694485a6af8565d1e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. J. Clark
3. S. Bellentani
4. A. Diehl
5. E. Brunt
6. C. Day
7. R. Lopez
8. L. Henry

In Hepatology

1. Z. Younossi
2. J. Clark
3. R. Lopez
4. E. Brunt
5. A. Diehl
6. S. Bellentani
7. C. Day
8. Z. Goodman

In Pathology and Forensic Medicine

1. J. Clark
2. E. Brunt
3. R. Lopez
4. S. Harrison
5. L. Henry
6. Z. Younossi
7. S. Bellentani
8. C. Day

Citations in the corpus

• Pathogenesis of non-alcoholic fatty liver disease (2009, background): “In a recent US study, NASH was found to account for at least 13% of overall cases of HCC.(23) There are as yet few proven therapies available for patients with NASH, and current strategies are directed towards improving aspects of the metabolic syndrome.”
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 (2015, result): “In fact, data reported from tertiary care centers have already indicated cryptogenic cirrhosis (presumed NAFLD cirrhosis) as an important cause of HCC.(27) Our finding builds on the data from tertiary care medical centers and highlights the importance of screening these patients for HCC.”
• The prevalence and etiology of elevated aminotransferase levels in the United States (2003, background): “First, in biopsy studies of patients referred for aminotransferase elevations, NAFLD was the most common histological finding (3, 22–24).”
• The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (2010, background): “Our results are consistent with other reports.(22-24) As such, patients with NASH-cirrhosis should be closely monitored for HCC.”
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, background): “In summary, our data confirm that patients with NASH are at high risk for LRM.(1-14,21-30) We have also shown that a certain degree of agreement exists between all four sets of pathologic criteria for NASH.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “The latter is often diagnosed at a late stage [51,59,61,63], and may occasionally occur in non-cirrhotic NASH [64].”